Piper Sandler Cuts ASLAN Pharmaceuticals Price Target to 3.00
ASLNDelisted Stock | USD 0.60 0.03 4.76% |
About 61% of Aslan Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Aslan Pharmaceuticals suggests that many traders are alarmed regarding Aslan Pharmaceuticals' prospects. Aslan Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Aslan Pharmaceuticals. Many technical investors use Aslan Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Aslan |
ASLAN Pharmaceuticals had its price objective lowered by Piper Sandler from 4.00 to 3.00 in a research report released on Monday morning, The Fly reports. Piper Sandler currently has an overweight rating on the stock. Separately, HC Wainwright decreased their target price on shares of ASLAN Pharmaceuticals from 7.00 to 4.50
Read at thelincolnianonline.com
Aslan Pharmaceuticals Fundamental Analysis
We analyze Aslan Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aslan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aslan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Aslan Pharmaceuticals is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Aslan Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aslan Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aslan Pharmaceuticals Related Equities
ASMB | Assembly Biosciences | 1.86 | ||||
ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
ADAG | Adagene | 0.47 | ||||
AVTE | Aerovate Therapeutics | 1.14 | ||||
NAMS | NewAmsterdam Pharma | 1.88 | ||||
IVA | Inventiva | 1.98 | ||||
CGEM | Cullinan Oncology | 2.56 | ||||
ACHL | Achilles Therapeutics | 2.86 | ||||
ANTX | AN2 Therapeutics | 4.52 | ||||
LYRA | Lyra Therapeutics | 4.76 | ||||
CTMX | CytomX Therapeutics | 5.08 | ||||
ERAS | Erasca | 5.40 | ||||
ACRV | Acrivon Therapeutics, | 5.65 | ||||
IOBT | IO Biotech | 5.95 | ||||
MLYS | Mineralys Therapeutics, | 6.02 | ||||
GPCR | Structure Therapeutics | 7.42 | ||||
TIL | Instil Bio | 7.67 | ||||
GLUE | Monte Rosa | 8.46 | ||||
CMPX | Compass Therapeutics | 9.58 | ||||
AGIO | Agios Pharm | 11.99 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Transaction History View history of all your transactions and understand their impact on performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |